News Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:32:57 2025-12-12 am EST			5-day change	1st Jan Change
123.20 ^USD	-0.01%		+1.67%	+33.43%

10:23am	Arcus Biosciences, Inc. Provides Update on Phase 3 Star-221 Study and Concentrates Its R&D Investment on Cas Datifan and Emerging Inflammation and Immunology Portfolio	CI
09:28am	Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update	DJ

Arcus Biosciences, Inc. Provides Update on Phase 3 Star-221 Study and Concentrates Its R&D Investment on Cas Datifan and Emerging Inflammation and Immunology Portfolio	10:23am	CI
Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update	09:28am	DJ
Morgan Stanley Adjusts PT on Gilead Sciences to $151 From $147, Maintains Overweight Rating	09:21am	MT
Arcus Biosciences Discontinuing Gastric, Esophogeal Cancer Candidate Trial; Shares Fall	09:13am	MT
Arcus Biosciences to Discontinue Phase 3 Trial of Potential Cancer Treatment	09:02am	DJ
Arcus scraps late-stage cancer trial after weak survival data	08:44am	RE
Gilead Sciences : Provides Update on Phase 3 STAR-221 Study	08:25am	PU
This Is Decision Day	Dec. 10
Wells Fargo Adjusts Price Target on Gilead Sciences to $150 From $145, Maintains Overweight Rating	Dec. 10	MT
HSBC Adjusts Price Target on Gilead Sciences to $133 From $110, Maintains Hold Rating	Dec. 10	MT
Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…	Dec. 10
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer	Dec. 09	BU
Arcellx, Inc. Announces New Positive Data from Its Pivotal Phase 2 iMMagine-1 Study of Anitocabtage Neautoleucel in Patients with Relapsed or Refractory Multiple Myeloma	Dec. 08	CI
Assembly Biosciences Reports Positive Interim Results from Phase 1B Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates Abi-1179 and Abi-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirms Genital Herpes	Dec. 08	CI
Gilead Sciences' Kite Says Yescarta Shows 'Consistent' Benefits in Large B-cell Lymphoma	Dec. 08	MT
Gilead Unit Reports Encouraging Phase 1 Data Showing High Response Rates for Bicistronic CAR T-Cell Candidates in B-Cell Lymphoma	Dec. 08	MT
Arcellx Says Phase 2 Cancer Study Shows 96% Overall Response Rate; Shares Up Pre-Bell	Dec. 08	MT
Lilly's Jaypirca met primary endpoint in head-to-head phase 3 study versus Imbruvica	Dec. 07	RE
Gilead Sciences : Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025	Dec. 07	PU
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025	Dec. 07	BU
Kite announces new data for pivotal Immagine-1 study at ASH 2025, highlighting anito-cel's opportunity in relapsed or refractory multiple myeloma	Dec. 06	RE
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025	Dec. 06	BU
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma	Dec. 06	BU
Sprint Bioscience (Q3 review) - Gilead deal a strong confirmation	Dec. 05	AQ
Soleno Therapeutics, Inc. Announces Demise of William G. Harris, Member of Board of Directors and Audit Committee Changes	Dec. 03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Time To Grow PFL Fanbase, Revenue: CEO John Martin

July 11, 2025 at 04:09 am EDT